Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 24, 2025
Daily News
March 24, 2025
- MHLW Panel Discusses Ways to Promote Clinical Trials
March 24, 2025
- Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
- PMDA Issues Guidance for Pediatric Drug Development
March 24, 2025
- Strattera Stock Expected to Run Out as Lilly's Talks with Regulators Drag On
March 24, 2025
- FPMAJ Maps Out Planned Activities for FY2025
March 24, 2025
- Mitsubishi Seeks Uplizna Nod for IgG4-Related Disease in Japan
March 24, 2025
- Keytruda Filed for Perioperative Use for Head and Neck Cancer in Japan
March 24, 2025
- Departing Employee Stole Personal Data on 5,200 People: MSD
March 24, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…